Here, we showed that the RAF and MEK pathways were transcriptionally upregulated in DSRCT tumors compared to other sarcomas and that treatment of DSRCT cells with EGF or HB-EGF caused only a small increase in ERK1/2 phosphorylation, probably due to high basal activation of the MAPK pathway by EWS-WT1. The gene discussed is MAPK3; the disease is sarcoma.